Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 777

1.

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators..

Clin Cardiol. 2017 Mar 15. doi: 10.1002/clc.22692. [Epub ahead of print]

2.

Time Trends and Educational Inequalities in Out-of-Hospital Coronary Deaths in Norway 1995-2009: A Cardiovascular Disease in Norway (CVDNOR) Project.

Sulo E, Nygård O, Vollset SE, Igland J, Ebbing M, Østbye T, Jørgensen T, Sulo G, Tell GS.

J Am Heart Assoc. 2017 Feb 20;6(2). pii: e005236. doi: 10.1161/JAHA.116.005236.

3.

Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Non-Obstructive Coronary Artery (MINOCA) Disease.

Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld AM, Gard A, Jernberg T.

Circulation. 2017 Feb 8. pii: CIRCULATIONAHA.116.026336. doi: 10.1161/CIRCULATIONAHA.116.026336. [Epub ahead of print]

PMID:
28179398
4.

Urinary 11-Dehydro-Thromboxane B<sub>2</sub> and Mortality in Patients With Stable Coronary Artery Disease.

McCullough PA, Vasudevan A, Sathyamoorthy M, Schussler JM, Velasco CE, Lopez LR, Swift C, Peterson M, Bennett-Firmin J, Schiffmann R, Bottiglieri T.

Am J Cardiol. 2017 Apr 1;119(7):972-977. doi: 10.1016/j.amjcard.2016.12.004.

PMID:
28139223
5.

Long-term hormone therapy for perimenopausal and postmenopausal women.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J.

Cochrane Database Syst Rev. 2017 Jan 17;1:CD004143. doi: 10.1002/14651858.CD004143.pub5. Review.

PMID:
28093732
6.

'Betwixt and between health and illness' - women's narratives following acute coronary syndrome.

Smith R, Frazer K, Hall P, Hyde A, O'Connor L.

J Clin Nurs. 2017 Jan 5. doi: 10.1111/jocn.13711. [Epub ahead of print]

PMID:
28054410
7.

Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland.

Prami T, Khanfir H, Deleskog A, Hasvold P, Kytö V, Reissell E, Airaksinen J.

BMJ Open. 2016 Nov 22;6(11):e012604. doi: 10.1136/bmjopen-2016-012604.

8.

Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.

Ladapo JA, Hoffmann U, Lee KL, Coles A, Huang M, Mark DB, Dolor RJ, Pelberg RA, Budoff M, Sigurdsson G, Severance HW, Douglas PS.

J Am Heart Assoc. 2016 Oct 12;5(10). pii: e003807.

9.

Kinesiophobia mediates the influences on attendance at exercise-based cardiac rehabilitation in patients with coronary artery disease.

Bäck M, Cider Å, Herlitz J, Lundberg M, Jansson B.

Physiother Theory Pract. 2016 Nov;32(8):571-580.

PMID:
27726471
10.

Physical inactivity and low quality of life of Turkish women after hospitalization for coronary heart disease: Inferences from EUROASPIRE III.

Tokgözoğlu L, Okutucu S, Kaya EB, Erol Ç, Ergene O.

Turk Kardiyol Dern Ars. 2016 Sep;44(6):488-97. doi: 10.5543/tkda.2016.30788.

11.

Sudden cardiac death: A reappraisal.

Steinberg C, Laksman ZW, Krahn AD.

Trends Cardiovasc Med. 2016 Nov;26(8):709-719. doi: 10.1016/j.tcm.2016.05.006. Review.

PMID:
27665048
12.

Prevalence of coronary heart disease in rural and urban Vellore: A repeat cross-sectional survey.

Oommen AM, Abraham VJ, George K, Jose VJ.

Indian Heart J. 2016 Jul-Aug;68(4):473-9. doi: 10.1016/j.ihj.2015.11.015.

13.

Trends in major risk factors and mortality from main non-communicable diseases in Lithuania, 1985-2013.

Tamosiunas A, Klumbiene J, Petkeviciene J, Radisauskas R, Vikhireva O, Luksiene D, Virviciute D.

BMC Public Health. 2016 Aug 4;16:717. doi: 10.1186/s12889-016-3387-0.

14.

Estrogens and Coronary Artery Disease: New Clinical Perspectives.

Meyer MR, Barton M.

Adv Pharmacol. 2016;77:307-60. doi: 10.1016/bs.apha.2016.05.003.

PMID:
27451102
15.

Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease.

Peeters G, Tett SE, Hollingworth SA, Gnjidic D, Hilmer SN, Dobson AJ, Hubbard RE.

J Gerontol A Biol Sci Med Sci. 2017 Feb;72(2):259-265. doi: 10.1093/gerona/glw111.

PMID:
27384327
16.

Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions.

Scott JM, Adams SC, Koelwyn GJ, Jones LW.

Can J Cardiol. 2016 Jul;32(7):881-90. doi: 10.1016/j.cjca.2016.03.014. Review.

PMID:
27343744
17.

Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.

Timmis A, Rapsomaniki E, Chung SC, Pujades-Rodriguez M, Moayyeri A, Stogiannis D, Shah AD, Pasea L, Denaxas S, Emmas C, Hemingway H.

BMJ. 2016 Jun 22;353:i3163. doi: 10.1136/bmj.i3163.

18.

Patient characteristics and risk factors of participants and non-participants in the NOR-COR study.

Munkhaugen J, Sverre E, Peersen K, Egge Ø, Gjertsen Eikeseth C, Gjertsen E, Gullestad L, Erik Otterstad J, Husebye E, Dammen T.

Scand Cardiovasc J. 2016 Oct - Dec;50(5-6):317-322.

PMID:
27323914
19.

Hormonalna terapia zastępcza a choroby układu sercowo-naczyniowego.

Lesiak M, Mariola RL, Podkowa N.

Ginekol Pol. 2016;87(1):59-64. doi: 10.17772/gp/61022.

20.

Sex hormone therapy and progression of cardiovascular disease in menopausal women.

Alhurani RE, Chahal CA, Ahmed AT, Mohamed EA, Miller VM.

Clin Sci (Lond). 2016 Jul 1;130(13):1065-74. doi: 10.1042/CS20160042. Review.

Supplemental Content

Loading ...
Support Center